Autori: Reck Martin
| Naslov | Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial (Article) |
| Autori | Reck Martin ... Andric Zoran G ... (broj koautora 18) |
| Info | JOURNAL OF THORACIC ONCOLOGY, (2024), vol. 19 br. 2, str. 297-313 |
| Projekat | Healthcare business of Merck KGaA, Darmstadt, Germany; Pfizer |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: |
